Anakinra
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Anakinra: From IL-1 Receptor Blockade to Extracutaneous Mastocytoma
One-Sentence Summary
Anakinra (marketed as Kineret) is a recombinant interleukin-1 (IL-1) receptor antagonist that is already marketed in the US. The TxGNN model predicts it may be effective for extracutaneous mastocytoma, but this is a graph-based prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Extracutaneous mastocytoma |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA103950, a biologics license) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on the rationale provided, anakinra blocks IL-1 receptor signaling.
Mastocytoma is a neoplastic proliferation of mast cells driven mainly by KIT. No mechanistic rationale connecting IL-1 blockade to this disease is evident from the data provided. The very high TxGNN score reflects a pattern in the knowledge graph, not biological or clinical support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA103950 | Kineret | Injection, solution | Swedish Orphan Biovitrum AB (publ) |
Safety Considerations
Please refer to the package insert for safety information. No drug-interaction records were found in the data provided.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction rests on model score alone: no trials, no literature, and no plausible IL-1 mechanism for a KIT-driven neoplasm.
To proceed, the following is needed:
- Any preclinical or clinical evidence linking IL-1 signaling to mast cell neoplasms
- Mechanism of action data (DrugBank) and package insert warnings and contraindications (FDA)
Other candidates in the same pack are better supported and worth prioritizing instead:
- Pyogenic autoinflammatory syndrome (score 99.83%, L3, Research Question): PSTPIP1 mutations drive excess IL-1 beta. Two anakinra-specific papers were retrieved: a 2023 scoping review of anakinra and canakinumab in PSTPIP1-associated diseases (PMID 38259483) and a 2024 case report and review in PAPASH (PMID 39006661). There are no interventional trials, and only 10 of the 19 listed publications were provided.
- Autosomal recessive familial Mediterranean fever (score 99.89%, L5, Research Question): biologically plausible, but no trials or literature were supplied. Literature on colchicine-resistant FMF should be reviewed before any upgrade.
- Unclassified autoinflammatory syndrome (score 99.81%, L3, Research Question): retrospective anakinra experience in pediatric rheumatic diseases (PMID 36589607), not specific to this category.
- Aggressive systemic mastocytosis: the two retrieved papers concern Schnitzler syndrome and are indirect at best, so they do not support this indication.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.